Axsome Therapeutics, Inc. (AXSM) Down 5.7% — Should I Book It and Bail?
Axsome Therapeutics, Inc. (AXSM) is under pressure this Tuesday, last changing hands at $182.83 on the NASDAQ. That is an $11.06 decline from the prior close of $193.89. The drop extends a retreat that has already carried the stock about 29.7% below its 52-week high of $260.19, reached on June 18, 2026. Shares still sit roughly 57.4% above the bottom of the 52-week range at $116.18, so the longer-term gains remain intact. Even so, the past three months have steadily eroded the momentum that carried the stock to its summer peak.
Volume is running at about 738,807 shares against a 90-day average of roughly 789,664. With the session still open, turnover is tracking close to normal levels. The decline is coming on steady trading rather than a surge in activity.
Why Axsome Therapeutics, Inc. Price is Moving Lower
The selling looks stock-specific, with a softer market adding to the pressure. Deutsche Bank lowered its AXSM price target from $280 to $267 on September 29, while keeping its Buy rating. A $13 trim that still implies meaningful upside is hardly a bearish call. But for a stock already about 30% off its June high, any step back in Wall Street's expectations gives holders one more reason to take risk off the table. AXSM's decline is running far steeper than the broader group. The SPDR S&P Biotech ETF (XBI) was down about 0.73%, and among sector peers Roivant Sciences Ltd. (ROIV) slipped 2.45%, while Moderna, Inc. (MRNA) gained 0.89%.
The macro backdrop is not helping. The 10-year Treasury yield climbed to 5.28%, and the S&P 500 was down about 0.3% in morning trading, according to the Associated Press. Rising rates weigh especially hard on companies that are still losing money. Much of a name like Axsome's valuation rests on earnings expected years from now, and higher discount rates cut into what those future profits are worth today.
The fundamental picture adds a layer of caution that predates today's session. Axsome's Q2 report in August showed a loss of $0.99 per share, wider than the $0.89 loss analysts expected. Revenue of $218.38 million also came in short of the $221.11 million consensus. The top line still grew 46% from $150.04 million a year earlier, so the commercial business is clearly expanding. However, net loss widened to $51.3 million from $48.0 million, which means revenue growth is not yet closing the gap to profitability. That earnings miss, combined with the reduced price target and a rate-driven risk-off tone, explains why AXSM is falling far faster than its sector today.
What is the Axsome Therapeutics, Inc. Rating - Should I Sell?
Weiss Ratings assigns AXSM a D- rating. Current recommendation is Sell. A D- places Axsome near the lower end of the Weiss scale. It reflects a company whose commercial progress has not yet translated into the kind of financial profile that justifies the risk of owning the shares.
The clearest strength is the balance sheet, which is rated Excellent on the Solvency Index. For a company still posting quarterly losses, that rating matters. Axsome is expanding sales of three marketed products and advancing a late-stage pipeline, and it can do so without immediate financing strain. That flexibility lowers the risk of dilution or forced partnerships while the company works toward profitability. The Growth Index is rated Fair, which may look conservative given revenue growth of 45.54% and a 14.2% sequential increase from $191.20 million in the first quarter to $218.38 million in the second. The rating stops at Fair because that growth is not reaching the bottom line. EPS stands at -$3.76, and the latest quarter's loss was wider than both the prior-year figure and analyst expectations.
Where the picture turns decisively negative is the Efficiency Index, rated Very Weak. A profit margin of -24.67% means Axsome still spends well beyond what its products bring in. The company is carrying heavy commercial and development costs for Auvelity, Sunosi, and Symbravo while funding multiple pipeline programs at the same time. A forward P/E of -51.57 shows that the market does not expect profits in the near term either. This is the single biggest weight on the overall rating.
The Total Return Index and the Volatility Index are both rated Fair, and the stock's trading history explains both ratings. Shareholders who bought near the 52-week low of $116.18 are still sitting on substantial gains. Anyone who bought near the $260.19 peak in June has absorbed a decline of nearly 30%. That spread between the low and high, together with today's 5.70% drop following the price target cut and the earnings shortfall, shows why the Volatility Index is not rated higher. Within the Health Care sector, Axsome sits alongside Moderna, Inc. (MRNA, D-), Roivant Sciences Ltd. (ROIV, D-), and Revolution Medicines, Inc. (RVMD, D-). It trails Zoetis Inc. (ZTS, D), which carries a slightly better but still Sell-rated profile.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) is a Health Care company focused on developing and commercializing therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. It has built a commercial portfolio of three approved products. The lead product is Auvelity, a dextromethorphan-bupropion combination for major depressive disorder in adults. Sunosi, or solriamfetol, treats excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Symbravo, a rapidly absorbed combination of meloxicam and rizatriptan, is indicated for the acute treatment of migraine with or without aura.
The pipeline is where much of Axsome's long-term value proposition sits. AXS-05, the same dextromethorphan-bupropion combination behind Auvelity, has completed Phase III testing in Alzheimer's disease agitation. A condition that affects both patients and caregivers could meaningfully broaden the drug's market. AXS-05 has also completed a Phase II trial in smoking cessation, supported by a research collaboration with Duke University. AXS-12, based on reboxetine, has completed Phase II testing in narcolepsy. AXS-14, or esreboxetine, has completed Phase III testing in fibromyalgia. Solriamfetol is in Phase III trials for attention deficit hyperactivity disorder, major depressive disorder, binge eating disorder, and excessive sleepiness associated with shift work disorder.
Axsome's competitive position comes from reusing molecules across related neurological and psychiatric indications. That approach lets the company get more mileage out of the clinical, regulatory, and commercial groundwork already built for each drug. A sales force already calling on psychiatrists, neurologists, and sleep specialists gives new indications a ready path to prescribers. Even so, CNS drug development carries high clinical and regulatory risk, and payer coverage in these markets remains competitive.
Investor Outlook
Axsome Therapeutics, Inc. (AXSM) carries a Weiss Rating of D- (Sell). Rapid revenue growth, widening losses, and pressure from rising Treasury yields argue for caution until the path to profitability becomes clearer. Investors should watch whether upcoming quarterly results can narrow the $51.3 million net loss while sustaining sales growth above 40%. They should also track regulatory progress on AXS-05 in Alzheimer's agitation, the pipeline event with the greatest potential to change the company's financial trajectory. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--